M Di Nisio1,2, M Candeloro3, A W S Rutjes4,5, E Porreca6. 1. Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. 2. Department of Medicine and Ageing Sciences, University G. D'Annunzio, Chieti-Pescara, Italy. 3. Department of Internal Medicine, Ospedale SS.Ma Annunziata, Chieti, Italy. 4. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. 5. Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. 6. Department of Medical, Oral and Biotechnological Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Abstract
Essentials Cancer patients are at risk for venous thromboembolism (VTE). The risk of VTE in less advanced stage cancer on neoadjuvant chemotherapy is unclear. In over 7800 patients, we found a 7% pooled incidence of VTE during neoadjuvant therapy. Highest VTE rates were observed in patients with bladder and esophageal cancer. SUMMARY: Background Venous thromboembolism (VTE) is a frequent complication in cancer patients receiving adjuvant treatment. The risk of VTE during neoadjuvant chemo-radiotherapy remains unclear. Objectives This systematic review evaluated the incidence of VTE in patients with cancer receiving neoadjuvant treatment. Methods MEDLINE and EMBASE databases were searched from inception to October 2017. Search results were supplemented with screening of conference proceedings of the American Society of Clinical Oncology (2009-2016) and the International Society of Thrombosis and Haemostasis (2003-2016). Two review authors independently screened titles and abstracts, and extracted data onto standardized forms. Results Twenty-eight cohort studies (7827 cancer patients, range 11 to 1398) were included. Twenty-five had a retrospective design. Eighteen cohorts included patients with gastrointestinal cancer, representing over two-thirds of the whole study population (n = 6002, 78%). In total, 508 of 7768 patients were diagnosed with at least one VTE during neoadjuvant treatment, for a pooled VTE incidence of 7% (95% CI, 5% to 10%) in the absence of substantial between-study heterogeneity. Heterogeneity was not explained by site of cancer or study design characteristics. VTE presented as pulmonary embolism in 22% to 96% of cases (16 cohorts), and it was symptomatic in 22% to 100% of patients (11 cohorts). The highest VTE rates were observed in patients with bladder (10.6%) or esophageal (8.4%) cancer. Conclusions This review found a relatively high incidence of VTE in cancer patients receiving neoadjuvant therapy in the presence of some between-study variation, which deserves further evaluation in prospective studies.
Essentials Cancerpatients are at risk for venous thromboembolism (VTE). The risk of VTE in less advanced stage cancer on neoadjuvant chemotherapy is unclear. In over 7800 patients, we found a 7% pooled incidence of VTE during neoadjuvant therapy. Highest VTE rates were observed in patients with bladder and esophageal cancer. SUMMARY: Background Venous thromboembolism (VTE) is a frequent complication in cancerpatients receiving adjuvant treatment. The risk of VTE during neoadjuvant chemo-radiotherapy remains unclear. Objectives This systematic review evaluated the incidence of VTE in patients with cancer receiving neoadjuvant treatment. Methods MEDLINE and EMBASE databases were searched from inception to October 2017. Search results were supplemented with screening of conference proceedings of the American Society of Clinical Oncology (2009-2016) and the International Society of Thrombosis and Haemostasis (2003-2016). Two review authors independently screened titles and abstracts, and extracted data onto standardized forms. Results Twenty-eight cohort studies (7827 cancerpatients, range 11 to 1398) were included. Twenty-five had a retrospective design. Eighteen cohorts included patients with gastrointestinal cancer, representing over two-thirds of the whole study population (n = 6002, 78%). In total, 508 of 7768 patients were diagnosed with at least one VTE during neoadjuvant treatment, for a pooled VTE incidence of 7% (95% CI, 5% to 10%) in the absence of substantial between-study heterogeneity. Heterogeneity was not explained by site of cancer or study design characteristics. VTE presented as pulmonary embolism in 22% to 96% of cases (16 cohorts), and it was symptomatic in 22% to 100% of patients (11 cohorts). The highest VTE rates were observed in patients with bladder (10.6%) or esophageal (8.4%) cancer. Conclusions This review found a relatively high incidence of VTE in cancerpatients receiving neoadjuvant therapy in the presence of some between-study variation, which deserves further evaluation in prospective studies.
Authors: Kristen McAlpine; Rodney Breau; Marc Carrier; Philippe Violette; Christopher Knee; Ilias Cagiannos; Christopher Morash; Luke Lavallée Journal: Can J Surg Date: 2020-11-30 Impact factor: 2.089
Authors: Andrew Amenyogbe; Francis Lemire; David Yachnin; Marc Carrier; Kristen McAlpine; Rodney H Breau; Dominick Bossé; Tzu-Fei Wang; Christopher Morash; Ilias Cagiannos; Luke T Lavallée Journal: Can Urol Assoc J Date: 2022-10 Impact factor: 2.052
Authors: F I Mulder; A Hovenkamp; H W M van Laarhoven; H R Büller; P W Kamphuisen; M C C M Hulshof; M I van Berge Henegouwen; S Middeldorp; N van Es Journal: Br J Surg Date: 2020-05-19 Impact factor: 6.939
Authors: Adam Ostrowski; Piotr Skrudlik; Filip Kowalski; Paweł Lipowski; Magdalena Ostrowska; Przemysław Adamczyk; Jan Adamowicz; Tomasz Drewa; Kajetan Juszczak Journal: Cent European J Urol Date: 2022-04-14